Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (LSE:0A4C) with a Market Perform recommendation. There are 326 funds or institutions reporting positions in ...

William Blair started coverage on shares of Altimmune in a research note on Friday. They issued a “market perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $ ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

William Blair International Leaders Fund earns an Average Process Pillar rating. The leading factor in the rating is the stability of the management team. Specifically, the fund has not seen a ...

William Blair Global Leaders Fund earns a Below Average Process Pillar rating. The process is bolstered by low costs across its parent firm's funds, whose fees rank in their respective category's ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever This table compares Li-Cycle and Decent’s net margins, return on equity and ...

The Fund seeks long-term capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of equity securities, including common ...